JP7249279B2 - がんの相乗的治療方法 - Google Patents
がんの相乗的治療方法 Download PDFInfo
- Publication number
- JP7249279B2 JP7249279B2 JP2019531255A JP2019531255A JP7249279B2 JP 7249279 B2 JP7249279 B2 JP 7249279B2 JP 2019531255 A JP2019531255 A JP 2019531255A JP 2019531255 A JP2019531255 A JP 2019531255A JP 7249279 B2 JP7249279 B2 JP 7249279B2
- Authority
- JP
- Japan
- Prior art keywords
- dose
- chemotherapeutic agent
- salmonella typhimurium
- agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
本願は、2016年12月7日出願の米国特許出願第62/430,962号に対する優先権を主張する。同出願の全内容は本明細書中に援用される。
BALB-neuTモデルは遺伝子改変マウスモデルで、ヒト上皮細胞増殖因子受容体2の恒常活性化したラット相同体を発現させることによって乳房腫瘍を発症させられている。このモデルでは自発性腫瘍が数か月の間に発症し、約16週齢の雌のマウスの乳房組織で触知できる。この腫瘍は、ヒト患者に見られるHer2により発生した悪性度の高いがんによく似ている。
(方法)
(結果)
Claims (15)
- 乳がんの治療方法で使用するための抗腫瘍薬であって、一用量のドキソルビシンを含む化学療法薬と一用量の切断型ヒトインターロイキン2をコードするコード配列を有するプラスミドを含む弱毒化ネズミチフス菌の組み合わせを含み、前記切断型ヒトインターロイキン2は配列番号2に示されるアミノ酸配列からなり、前記方法は、
一用量の前記化学療法薬と一用量の前記切断型ヒトインターロイキン2をコードするコード配列を有する前記プラスミドを含む前記弱毒化ネズミチフス菌の前記組み合わせを投与することを含み、
前記化学療法薬の用量は、前記化学療法薬の最大有効量よりも少なく、
前記組み合わせは、同用量の前記化学療法薬を前記切断型ヒトインターロイキン2をコードするコード配列を有するプラスミドを含む前記弱毒化ネズミチフス菌なしで投与した場合の腫瘍量の減少に比べて腫瘍量を相乗的に減少させ、かつ
前記組み合わせの毒性は最大有効量の前記化学療法薬の毒性よりも低い、
抗腫瘍薬。 - 前記化学療法薬の用量は約1.25mg/kg以下である、請求項1に記載の抗腫瘍薬。
- 前記化学療法薬の用量は前記化学療法薬の最大有効量の25%である、請求項1に記載の方法。
- 前記切断型ヒトインターロイキン2をコードするコード配列を有する前記プラスミドを含む弱毒化ネズミチフス菌の前記用量は約1×109コロニー形成単位である、請求項1に記載の抗腫瘍薬。
- 前記切断型ヒトインターロイキン2をコードするコード配列を有する前記プラスミドを含む前記弱毒化ネズミチフス菌は経口投与される、請求項1に記載の抗腫瘍薬。
- 第1の用量の前記化学療法薬と前記用量の前記切断型ヒトインターロイキン2をコードするコード配列を有する前記プラスミドを含む前記弱毒化ネズミチフス菌が第1の日に投与される、請求項1に記載の抗腫瘍薬。
- 第2の用量の前記化学療法薬が前記第1の日の1週間後の第2の日に投与される、請求項6に記載の抗腫瘍薬。
- 第3の用量の前記化学療法薬が前記第2の日の1週間後の第3の日に投与される、請求項7に記載の抗腫瘍薬。
- 複数の用量の前記化学療法薬と複数の用量の前記弱毒化ネズミチフス菌が前記第1の日の後の複数の日に投与される、請求項6に記載の抗腫瘍薬。
- 前記化学療法薬は、カルボプラチン、シスプラチン、シクロホスファミド、ダウノルビシン、オキサリプラチン、5-フルオロウラシル、またはゲムシタビンをさらに含む、請求項1に記載の抗腫瘍薬。
- 前記化学療法薬は、シスプラチン、シクロホスファミド、ダウノルビシン、オキサリプラチン、5-フルオロウラシル、またはゲムシタビンをさらに含む、請求項1に記載の抗腫瘍薬。
- 前記抗腫瘍薬は、前記組み合わせを投与した患者における体重減少を、該患者に前記化学療法薬の最大有効量を投与した場合に起こるであろう体重減少と比較して低減する、請求項1に記載の抗腫瘍薬。
- 前記化学療法薬の用量は約1.25mg/kgであり、前記切断型ヒトインターロイキン2をコードするコード配列を有する前記プラスミドを含む前記弱毒化ネズミチフス菌は経口投与される、請求項1に記載の抗腫瘍薬。
- 弱毒化ネズミチフス菌を含む、乳がんの治療方法で使用するための医薬組成物であって、
前記弱毒化ネズミチフス菌は切断型ヒトインターロイキン2をコードするコード配列を有するプラスミドを含み、前記切断型ヒトインターロイキン2は配列番号2に示されるアミノ酸配列からなり;
ここで、前記医薬組成物は、ドキソルビシンを含む化学療法薬を含むがんの治療方法で使用するための抗腫瘍薬との組み合わせで投与され、
ここで、前記化学療法薬の用量は、該化学療法薬の最大有効量よりも低く、
前記組み合わせは、同用量の前記化学療法薬を前記弱毒化ネズミチフス菌を含む組成物なしで投与した場合の腫瘍量の減少に比べて、腫瘍量の相乗的な減少をもたらし、
前記組み合わせの毒性は、最大有効量の前記化学療法薬の毒性よりも低い、医薬組成物。 - 化学療法薬を含む、乳がんの治療方法で使用するための抗腫瘍薬であって、
前記化学療法薬は、ドキソルビシンを含み、
前記抗腫瘍薬は、弱毒化ネズミチフス菌を含むがんの治療方法で使用するための医薬組成物との組み合わせで投与され、
前記弱毒化ネズミチフス菌は切断型ヒトインターロイキン2をコードするコード配列を有するプラスミドを含み、前記切断型ヒトインターロイキン2は配列番号2に示されるアミノ酸配列からなり;
ここで、前記化学療法薬の用量は、該化学療法薬の最大有効量よりも低く、
前記組み合わせは、同用量の前記化学療法薬を前記弱毒化ネズミチフス菌を含む組成物なしで投与した場合の腫瘍量の減少に比べて、腫瘍量の相乗的な減少をもたらし、
前記組み合わせの毒性は、最大有効量の前記化学療法薬の毒性よりも低い、抗腫瘍薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022143644A JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662430962P | 2016-12-07 | 2016-12-07 | |
US62/430,962 | 2016-12-07 | ||
PCT/US2017/064813 WO2018106754A1 (en) | 2016-12-07 | 2017-12-06 | Methods of synergistic treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022143644A Division JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020500922A JP2020500922A (ja) | 2020-01-16 |
JP2020500922A5 JP2020500922A5 (ja) | 2021-01-28 |
JP7249279B2 true JP7249279B2 (ja) | 2023-03-30 |
Family
ID=62492129
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019531255A Active JP7249279B2 (ja) | 2016-12-07 | 2017-12-06 | がんの相乗的治療方法 |
JP2022143644A Pending JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022143644A Pending JP2022171776A (ja) | 2016-12-07 | 2022-09-09 | がんの相乗的治療方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11576936B2 (ja) |
EP (1) | EP3550976A4 (ja) |
JP (2) | JP7249279B2 (ja) |
WO (1) | WO2018106754A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7097438B2 (ja) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
BR112021000315A2 (pt) | 2018-07-11 | 2021-08-03 | Actym Therapeutics, Inc. | cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos |
JP2023508988A (ja) * | 2019-12-26 | 2023-03-06 | サルスペラ,リミティド ライアビリティ カンパニー | 固形腫瘍がんを治療する方法および薬剤 |
EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
WO2023105076A1 (en) | 2021-12-09 | 2023-06-15 | Prokarium Limited | Combination cancer therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100098665A1 (en) | 2004-04-29 | 2010-04-22 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
WO2016145974A1 (zh) | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
AU1173700A (en) | 1998-12-03 | 2000-06-19 | Crede, Thomas | Enteral pharmaceutical preparation |
WO2001024637A1 (en) | 1999-10-04 | 2001-04-12 | Vion Pharmaceuticals, Inc. | Methods for treating solid tumors with irradiation and bacteria |
WO2002026819A2 (en) | 2000-09-26 | 2002-04-04 | Roger Williams Hospital | Recombinant bcg vaccines for the prevention and treatment of cancer |
US20080107758A1 (en) | 2001-06-15 | 2008-05-08 | Cuticeuticals, Inc. | Topical steroid spray with botanic seed oils |
WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
DE10208653A1 (de) | 2002-02-28 | 2003-09-18 | Medinnova Ges Med Innovationen | Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren |
DE602004018927D1 (de) | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
US20070128301A1 (en) | 2005-09-07 | 2007-06-07 | Saltzman Daniel A | Immune enhancement by seed oil and/or seed flour |
US20050244375A1 (en) | 2004-04-29 | 2005-11-03 | Leonard Arnold S | Composition and method of cancer treatment |
US7897194B2 (en) | 2006-04-18 | 2011-03-01 | Botanic Oil Innovations, Inc. | Synergistic super potent antioxidant cold pressed botanic oil blends |
BRPI0615593A2 (pt) | 2005-08-30 | 2011-05-24 | Commw Scient And Ind Reseaech Organisation | liberação bacteriana de polipeptìdeos biologicamente ativos |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
US9127284B2 (en) | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
-
2017
- 2017-12-06 US US16/467,338 patent/US11576936B2/en active Active
- 2017-12-06 WO PCT/US2017/064813 patent/WO2018106754A1/en unknown
- 2017-12-06 JP JP2019531255A patent/JP7249279B2/ja active Active
- 2017-12-06 EP EP17877671.2A patent/EP3550976A4/en active Pending
-
2022
- 2022-09-09 JP JP2022143644A patent/JP2022171776A/ja active Pending
-
2023
- 2023-01-26 US US18/159,934 patent/US20240091275A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100098665A1 (en) | 2004-04-29 | 2010-04-22 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
WO2016145974A1 (zh) | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
Non-Patent Citations (2)
Title |
---|
Oncotarget, Feb 2016, Vol. 7, No. 11, pp. 12783-12790 |
Veterinary Medicine and Science, Jun 2016, Vol. 2, pp. 179-190 |
Also Published As
Publication number | Publication date |
---|---|
US11576936B2 (en) | 2023-02-14 |
EP3550976A4 (en) | 2020-06-10 |
JP2020500922A (ja) | 2020-01-16 |
EP3550976A1 (en) | 2019-10-16 |
WO2018106754A1 (en) | 2018-06-14 |
JP2022171776A (ja) | 2022-11-11 |
US20240091275A1 (en) | 2024-03-21 |
US20200085883A1 (en) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7249279B2 (ja) | がんの相乗的治療方法 | |
Liang et al. | Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy | |
JP6616319B2 (ja) | 腫瘍崩壊ワクシニアウィルス | |
JP2020011966A (ja) | 増強された養子細胞療法 | |
US8221739B2 (en) | Method of cancer treatment | |
Saltzman et al. | Low dose chemotherapy combined with attenuated Salmonella decreases tumor burden and is less toxic than high dose chemotherapy in an autochthonous murine model of breast cancer | |
JP3013896B2 (ja) | ヒトマンガンスーパーオキシドジスムターゼを含む薬剤組成物 | |
CN116948931A (zh) | 靶向肿瘤和治疗癌症的细菌 | |
JP2777074B2 (ja) | ポリペプチドおよびその製造方法 | |
EP2364361A1 (en) | Use of bacteria for the sensing and killing of cancer cells | |
CN113499450A (zh) | 用于治疗疼痛的组合物 | |
US20080274121A1 (en) | Inhibition of Angiogenesis by Mithramycin | |
ES2267560T3 (es) | Secuencias de adn para mejorar la eficacia de alimentacion y la tasa de crecimiento en cerdos. | |
JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
KR20210107140A (ko) | 통증 완화 또는 치료용 조성물 | |
US20230057396A1 (en) | Methods and agents for treating solid tumor cancers | |
ES2847214T3 (es) | 8-oxo-dGTP para la prevención y tratamiento de tumores y aplicaciones del mismo | |
KR20240015029A (ko) | 카탈레이스 분비를 위한 재조합 발현 벡터 및 이로형질전환된 대장균 균주 | |
Günzburg et al. | Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer. | |
KR20240015038A (ko) | 인터루킨-21의 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주 | |
Zou et al. | Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery | |
KR20240054373A (ko) | 종양의 비독성 콜로니화를 위해 조작된 살모넬라 | |
Rivera et al. | 1048. Long-Term Regulated Gene Expression in Non-Human Primates Using a Single Non-Recombinogenic AAV Vector | |
Yu et al. | 1049. Engineered ZFPs Can Prevent Limb Loss in Mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201207 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220909 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220909 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220927 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221028 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230317 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7249279 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |